GlaxoSmithKline Aktie

17,74EUR
-0,72EUR
-3,90%
26.11.2021
15,19GBP
-0,21GBP
-1,34%
26.11.2021

WKN: 940561 / ISIN: GB0009252882

  Kaufen  
Verkaufen
oder
Werbung

GlaxoSmithKline Aktien News

15.11.21TUMS® Provides #TUMSworthy Holiday Hacks for Heartburn Inducing Moments this Thanksgiving with the Help of Comedian Ronny Chieng (PR Newswire)
05.11.21GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease (PR Newswire)
27.10.21GlaxoSmithKline erwirtschaftet höheren Umsatz und gibt Dividende bekannt (MyDividends)
26.10.21Theraflu Launches the Rest & Recover Fund to Help More Americans Take a Sick Day When Needed (PR Newswire)
07.10.21IIROC Trade Resumption - GSK (PR Newswire)
07.10.21IIROC Trade Resumption - GSK (PR Newswire)
06.10.21IIROC Trading Halt - GSK (PR Newswire)
06.10.21IIROC Trading Halt - GSK (PR Newswire)
28.09.21Sensodyne® Repair and Protect with Deep Repair is Proud to Deliver a Minty & Whitening Toothpaste, Just in Time for National Coffee Day (PR Newswire)
17.08.21
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours (EN, GlaxoSmithKline)
16.08.21
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study (EN, GlaxoSmithKline)
29.07.21
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
28.07.21
GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER Total EPS 27.9p -39% AER, -28% CER; Adjusted EPS 28.1p +46% AER +71% CER (EN, GlaxoSmithKline)
28.07.21GlaxoSmithKline kündigt Dividende an (MyDividends)
28.07.21
GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab (EN, GlaxoSmithKline)
26.07.21
Shingrix approved in the US for prevention of shingles in immunocompromised adults (EN, GlaxoSmithKline)
26.07.21Shingrix approved in the US for prevention of shingles in immunocompromised adults (PR Newswire)
22.07.21
Brian McNamara appointed CEO Designate of new independent Consumer Healthcare company (EN, GlaxoSmithKline)
17.07.21
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs (EN, GlaxoSmithKline)
17.07.21
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19 (EN, GlaxoSmithKline)
17.07.21
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021 (EN, GlaxoSmithKline)
16.07.21
GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease (EN, GlaxoSmithKline)
16.07.21
GSK unveils plan for one of Europe’s largest life science campuses in Stevenage (EN, GlaxoSmithKline)
15.07.21
New study shows more needs to be done to raise public awareness on the impact of good oral health habits on overall health (EN, GlaxoSmithKline)
02.07.21
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases (EN, GlaxoSmithKline)
02.07.21
Elliott Advisors (UK) letter to GSK (EN, GlaxoSmithKline)
29.06.21TUMS® Fuels the Autoburn, a Road Trip to America's Spiciest Destinations, with Hot Food Expert Sean Evans (PR Newswire)
23.06.21
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline (EN, GlaxoSmithKline)
22.06.21
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV (EN, GlaxoSmithKline)
22.06.21ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV (PR Newswire)
21.06.21
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab (EN, GlaxoSmithKline)
14.06.21
GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations (EN, GlaxoSmithKline)
01.06.21
GSK to showcase scientific advances and progress in oncology at ASCO and EHA (EN, GlaxoSmithKline)
27.05.21
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate (EN, GlaxoSmithKline)
26.05.21
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients (EN, GlaxoSmithKline)
26.05.21
GSK announced as a Principal Partner of COP26 UN Climate Change Conference (EN, GlaxoSmithKline)
21.05.21
EMA issues positive scientific opinion on GSK and Vir Biotechnology’s sotrovimab for the early treatment of COVID-19 (EN, GlaxoSmithKline)
20.05.21
GSK announces sale of stake in Innoviva Inc (EN, GlaxoSmithKline)
18.05.21
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate (EN, GlaxoSmithKline)
17.05.21
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial (EN, GlaxoSmithKline)
Seite: 123

GlaxoSmithKline News

GlaxoSmithKline News: auf dieser Seite finden Sie alle GlaxoSmithKline News und Nachrichten zur GlaxoSmithKline Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch GlaxoSmithKline News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um GlaxoSmithKline News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln